anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 222,121-222,150
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

222,121-222,150 of 303,780

filter-aware
33
The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
The slide uses a 2x2 grid to summarize the program's value proposition.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
The slide uses a Gantt-style visualization to show the progression of various IBD programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
42
The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
43
The slide uses a visual representation of a bispecific or combination antibody structure.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
45
The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
46
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
48
The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogee Therapeutics.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a series of icons to represent different scientific methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
55
The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
01
Slide 1
This is a branding/vision slide, likely the opening or a major section divider.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
02
arm | IPO Presentation Deck | 117 slidesarm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
03
This appears to be a transition or mood-setting slide in a pitch deck.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
04
The slide uses a lifestyle image to illustrate the product in use.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
05
The slide uses a high-quality lifestyle image to evoke an emotional connection to the educational aspect of the product.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
06
The slide uses a minimalist, aspirational aesthetic typical of a 'vision' or 'mission' slide in a pitch deck.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
07
arm | IPO Presentation Deck | 117 slidesarm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit
08
arm | IPO Presentation Deck | 117 slidesarm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank Beat · Problem1 hit